Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 16–Aug 23, 2026)

· 1 min read

Here’s what’s on the biotech calendar for August 16–August 23: 1 FDA decision dates, 1 trial catalysts, and 1 earnings reports from tracked companies.

💊 FDA Decisions (PDUFA Dates)

Date Ticker Drug Indication Type
2026-08-22 CAPR — rare diseases BLA

🧪 Trial Catalysts & Milestones

  • ARV — 2026-08-20: Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

📊 Earnings This Week

  • CADL — 2026-08-19 (est. EPS -0.2384)

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • CAPR — BLA in 6 days, score 80/100
  • SNDX — Phase 2 — Active Trial in 16 days, score 60/100
  • ORIC — Phase 1, Phase 2 — Recruiting in 16 days, score 60/100

📈 Last Week’s Biggest Gainers

  • ARX +43.35% (volume 33.6x average)
  • NBIS +34.14% (volume 3.1x average)
  • QNT +27.97% (volume 1.4x average)
  • NESR +23.33% (volume 4.0x average)
  • EROC +22.84% (volume 4.6x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.